raremaprare-disease reference indexOrphadata 2026-06-23 · HPO 2026-09-01
ORPHA:703

Bullous pemphigoid

Type
Disease
Group
Disorder
Inheritance
Not applicable
Age of onset
All ages
Status
active

A rare autoimmune bullous skin disease characterized by acquired, subepidermal tense bullae occurring on normal of inflamed skin and that is typically widespread (occurring in the flexor regions of the proximal arms and legs, in the armpits, groin and the abdomen) and often associated with pruritus. The evolution is typically chronic with spontaneous exacerbations and remission.

1

Names in Orphadata languages

12 of 12 languages
LangNameSynonyms
enBullous pemphigoid
frPemphigoïde bulleuse
dePemphigoid, bullöses
esPenfigoide ampollosoPenfigoide bulloso
itPemfigoide bolloso
nlBulleus pemfigoïd
ptPenfigoide bolhoso
plPemfigoid pęcherzowy
csBulózní pemfigoid
ukБульозний пемфігоїд
zh大疱性类天疱疮
trBüllöz pemfigoid

Definition in:

2

Cross-references

qualifier = Orphanet mapping relation
SourceCodeQualifierICD relationValidation
ICD-10L12.0Especificvalidated
ICD-11EB41.0Especificvalidated
MONDO0019082Evalidated
MeSHD010391Evalidated
UMLSC0030805Evalidated
GARD5972Evalidated
MedDRA10006567Evalidated

E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.

3

Classification

Preferential parent (Orphanet linearisation):

Parents in the classifications (1):

No children.

4

Genes

2 direct
GeneAssociationStatusHGNCEnsemblOMIMLocusNameSource of validation
HLA-DRB1Candidate gene tested inNot yet assessedHGNC:4948ENSG000001961261428576p21.32major histocompatibility complex, class II, DR beta 18710911[PMID]_23806156[PMID]
HLA-DQB1Major susceptibility factor inNot yet assessedHGNC:4944ENSG000001793446043056p21.32major histocompatibility complex, class II, DQ beta 18710911[PMID]_23806156[PMID]
5

Prevalence and incidence

6 records
TypeClassValueAreaQualificationValidationSource
Annual incidence1-9 / 100 0002.17 / 100 000FranceValue and classValidated22418872[PMID]_23237497[PMID]
Annual incidence1-9 / 100 0001.34 / 100 000GermanyValue and classValidated19170813[PMID]
Annual incidence1-9 / 100 0004.3 / 100 000United KingdomValue and classValidated18614511[PMID]
Annual incidence1-9 / 100 0001.21 / 100 000SwitzerlandValue and classValidated19566661[PMID]
Point prevalence1-5 / 10 00025 / 100 000EuropeValue and classValidatedEuropean Medicines Agency 2018[OTHER]
Point prevalence1-5 / 10 00025.93 / 100 000GermanyValue and classValidated27456755[PMID]

Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.

6

HPO phenotypes

15 annotations · validated 2023-09-18
HPOTerm (as annotated by Orphanet)Diagnostic
Very frequent (99-80%)
HP:0008066Abnormal blistering of the skin
HP:0002960Autoimmunity
HP:0000819Diabetes mellitus
HP:0000964Eczematoid dermatitis
HP:0010783Erythema
HP:0012733Macule
HP:0002719Recurrent infections
HP:0001025Urticaria
HP:0001824Weight loss
Frequent (79-30%)
HP:4000020Anti-BP180 antibody positivity
HP:4000019Anti-BP230 antibody positivity
HP:0033106Elevated circulating D-dimer concentration
HP:0000989Pruritus
HP:0003765Psoriasiform dermatitis
Occasional (29-5%)
HP:0200097Oral mucosal blisters

Run the differential on the 9 obligate / very frequent terms

Annotation source: 31090818[PMID]_282861095[PMID]

7

Sources for this card